VNA
MDGL icon

Valley National Advisers’s Madrigal Pharmaceuticals MDGL Stock Holding History

Valley National Advisers’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.4K Hold
161
– – 0.01% 344
2026
Q1 		$84K Hold
161
– – 0.01% 340
2025
Q4 		$93K Buy
161
+122
+313% +$62.3K 0.01% 321
2025
Q3 		$17K Buy
39
+4
+11% +$1.49K ﹤0.01% 489
2025
Q2 		$10K Buy
+35
New +$10.4K ﹤0.01% 560

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Valley National Advisers's MDGL Position: Q2 2026 in Review

Valley National Advisers held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 161 shares worth $86.4K. The position accounts for 0.01% of the portfolio, ranked #344.

Valley National Advisers first reported a position in MDGL in Q2 2025 and has held it in 5 quarters since. The position peaked at $93K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Valley National Advisers held 161 shares of Madrigal Pharmaceuticals worth $86.4K as of Q2 2026.
  • Valley National Advisers left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.01% of Valley National Advisers's portfolio in Q2 2026, its #344 holding.
  • Valley National Advisers first reported a position in Madrigal Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Valley National Advisers's Madrigal Pharmaceuticals position peaked at $93K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.